A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer
Clinical trial NCT00992186 · COMPLETED
Trial details
- NCT number
- NCT00992186
- Sponsor
- Centocor Research & Development, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-09-01
- Primary completion
- 2011-07-01
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.